Here's What Analysts Think About Thermo Fisher Scientific (TMO) Post Earnings

Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the best strong buy healthcare stocks to invest in. Thermo Fisher Scientific Inc. (NYSE:TMO) reported its fiscal Q4 and full-year 2025 results on January 29, announcing that fiscal Q4 revenue grew 7% to $12.21 billion. GAAP diluted earnings per share for the quarter grew 9% to $5.21, while adjusted EPS rose 8% to $6.57. In addition, full year revenue underwent a 4% growth to $44.56 billion, with GAAP diluted earnings per share rising 7% to $17.74, and adjusted EPS growing 5% to $22.87.

Following the earnings update, Thermo Fisher Scientific Inc. (NYSE:TMO) received several rating updates, including Citi lifting the price target on the stock to $685 from $660 on January 30 and maintaining a Buy rating on the shares. The same day, Baird also raised the price target on the stock to $653 from $645 and maintained an Outperform rating on the shares, telling investors that it updated its model on Thermo Fisher Scientific Inc. (NYSE:TMO) following its fiscal Q4 earnings release and adding that it remains a top idea.

Thermo Fisher Scientific Inc. (NYSE:TMO) provides analytical instruments, reagents, equipment, software, and other services for analysis, research, diagnostics, and discovery. It operates through the Analytical Instruments, Life Sciences Solutions, Laboratory Products and Services, and Specialty Diagnostics segments.

While we acknowledge the potential of TMO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.